Aridis Pharmaceuticals, Inc.·4/A

Dec 12, 11:39 AM ET

KURLAND FRED 4/A

4/A · Aridis Pharmaceuticals, Inc. · Filed Dec 12, 2018

Insider Transaction Report

Form 4/AAmended
Period: 2018-12-05
KURLAND FRED
Chief Financial Officer
Transactions
  • Award

    Stock Options

    2018-12-05+17,00039,574 total
    Exercise: $8.50Exp: 2028-12-05Common Stock (17,000 underlying)
Footnotes (2)
  • [F1]The shares underlying this stock option vest as follows: in equal annual installments over the 48 months following the date of grant.
  • [F2]Due to a clerical error, the reporting person is filing this Amendment to correct the amount of derivative securities beneficially owned following the reported transaction from 40,024 to 39,574.

Documents

1 file
  • 4
    a4a.xml

    4/A